banner2

Getting started
3-Chlorobenzyl Bromide CAS 766-80-3

3-Chlorobenzyl Bromide CAS 766-80-3 - China Factory, Suppliers, Manufacturers

3-Chlorobenzyl Bromide CAS 766-80-3, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

3-Chlorobenzyl Bromide CAS 766-80-3 Purity 97.0 (GC) Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — 3-Chlorobenzyl Bromide CAS 766-80-3 Purity >97.0% (GC) Factory
Read More

Darifenacin Hydrobromide Darifenacin HBr CAS 133099-07-7 Assay ≥99.0% API Factory High Quality

Teneligliptin Hydrobromide Teneligliptin HBr CAS 906093-29-6 CAS 906093-29-6 Purity >99.5% (HPLC) DPP-4 Inhibitor Factory

4-(Carboxybutyl)triphenylphosphonium Bromide CAS 17814-85-6 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — 4-(Carboxybutyl)triphenylphosphonium Bromide CAS 17814-85-6 Purity >98.0% (HPLC)

Tetrahydrofurfuryl Bromide CAS 1192-30-9 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Tetrahydrofurfuryl Bromide CAS 1192-30-9 Purity >98.0% (GC)

2-(Fmoc-Amino)ethyl Bromide CAS 340187-12-4 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — 2-(Fmoc-Amino)ethyl Bromide CAS 340187-12-4 Purity >98.0% (HPLC)

3-Chlorophenethyl Bromide CAS 16799-05-6 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — 3-Chlorophenethyl Bromide CAS 16799-05-6 Purity ≥97.0% (GC)

banner4

Top Selling Products

Related Blog
Reviews

Focus on Cross Border Integration of Biomedicine and Chemical Materials, October 15, 2021

Focus on Cross Border Integration of Biomedicine and Chemical Materials: New Opportunities, New Technologies and New Models This forum focuses on the interdisciplinary and cutting-edge technologies...
The Third Conference on Boron Chemistry of Chinese Chemical Society，CCS-CBS-III

The Third Conference on Boron Chemistry of Chinese Chemical Society (CCS-CBS) will be held in Suzhou, Jiangsu Province from October 15 to 18, 2021. This conference will be hosted by Inorganic Chemi...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
The 19th Beijing Conference and Exhibition on Instrumental Analysis (BCEIA 2021)-Shanghai Ruifu Chemical Co., Ltd. participated in the exhibition

The 19th Beijing Conference and Exhibition on Instrumental Analysis (BCEIA 2021) was held on September 27-29, 2021 at China International Exhibition Center (Tianzhu New Hall), Beijing. Adhering to...
Paxlovid: what we know about Pfizer's Covid-19 pill

Pfizer is seeking emergency use authorisation from the FDA for its novel Covid-19 antiviral pill Paxlovid. Share Article On the heels of Merck antiviral molnupiravir’s UK approval, Pfizer...
The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021

The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021 As the world’s second largest medical market, ...

2022.08.27 09:35:12
2022.06.22 23:32:25
2022.06.15 23:13:24
2022.02.02 15:29:38
2022.01.11 19:59:43
2021.12.17 17:08:41

related search